Previously we identified a sodium caseinate (NaCas) hydrolysate, LFC25, which significantly increased secretion of satiety hormone glucagon-like peptide-1 (GLP-1) in vitro and reduced food intake in mice when administered intraperitoneally. This study investigates whether LFC25, administered orally, promotes GLP-1 secretion and/or reduces food intake in vivo. Over an 8-hour period, mice received LFC25 by oral gavage had similar food intake to mice received NaCas. Postprandial blood glucose, plasma active GLP-1, amino acids, insulin and food consumed at the next meal were not significantly different in pigs that consumed LFC25 compared to NaCas in a dairy beverage, at a dosage relevant for human consumption. Simulated in vitro gastro-duodenal digestion of LFC25 revealed a significant reduction in bioactivity. In contrast, the harsh conditions of the upper gut appear to functionalize intact NaCas as a GLP-1 secretagogue. In conclusion, LFC25 will need enteric protection to be used as a food ingredient for satiety.

以前，我们确定酪蛋白酸钠（NaCas）水解产物LFC25，在体外腹腔给药时，其显着增加了饱腹感激素胰高血糖素样肽1（GLP-1）的分泌，并减少了小鼠的食物摄入。这项研究调查了口服LFC25是否在体内促进GLP-1分泌和/或减少食物摄入。在8小时内，通过口管饲喂LFC25的小鼠的食物摄入量与接受NaCas的小鼠相似。与牛奶中的NaCas相比，食用LFC25的猪的餐后血糖，血浆中的活性GLP-1，氨基酸，胰岛素和下一餐进食的食物与NaCas相比无显着差异，且剂量与人食用有关。体外模拟LFC25的胃十二指肠消化显示生物活性显着降低。相反，上消化道的恶劣条件似乎将完整的NaCas用作GLP-1促分泌素。总之，LFC25将需要肠溶保护作为饱腹感的食品成分。